(Q43971937)

28 November 2017

title

Preoperative treatment and surgery in gastric cancer: friends or foes? (English)

1 reference

28 November 2017

3

1 reference

28 November 2017

Domenico D'Ugo

1

1 reference

28 November 2017

Stefano Rausei

series ordinal

2

1 reference

28 November 2017

Roberto Persiani

series ordinal

4

1 reference

28 November 2017

publication date

1 February 2009

1 reference

Lancet Oncology Commission

28 November 2017

published in

1 reference

28 November 2017

volume

10

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

191-195

1 reference

A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Neoadjuvant chemotherapy for gastric cancer: update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Preoperative chemotherapy of locally advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Adjuvant therapy in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Chemoradiation for resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970021-X

7 January 2021

10.1016/S1470-2045(09)70021-X

Identifiers

DOI

1 reference

28 November 2017

1 reference